Sopan Pharmaceuticals IPO Allotment: 347,490 applicants received shares
30th April 2026, Kathmandu
The primary market in Nepal has reached a new milestone as Sopan Pharmaceuticals Limited officially concluded its share distribution process.
Sopan Pharmaceuticals IPO Allotment
This morning, the issue manager, NMB Capital Limited, successfully completed the Sopan Pharmaceuticals IPO Allotment for the shares recently offered to the general public. This event was highly anticipated by millions of retail investors who had applied for the offering during the subscription period. As the pharmaceutical sector gains more traction on the Nepal Stock Exchange, this successful allotment highlights the sector’s growing importance and the massive scale of public participation in the country’s capital market.
Massive Public Response and Subscription Statistics
Sopan Pharmaceuticals Limited opened its doors to public investment from Baisakh 3 to Baisakh 8, 2083. During this window, the company offered 3,474,900 shares at a standard face value of Rs 100 per share. The response from the investing community was nothing short of extraordinary. According to the data released by NMB Capital, the IPO received a total of 2,768,743 applications.
After a thorough verification process, the number of approved and valid applications stood at 2,730,987. This high level of interest underscores a significant trend in Nepal where retail investors are increasingly looking beyond traditional sectors like banking and hydropower to diversify their portfolios into healthcare and manufacturing.
Understanding the Lottery Based Allotment Process
Because the demand for shares was significantly higher than the available supply, the company had to follow the standard regulatory procedure of a lottery system. The Sopan Pharmaceuticals IPO Allotment results were determined through a fair and transparent draw overseen by the issue manager and regulatory observers.
Key highlights of the allotment include:
Lucky Winners: A total of 347,490 applicants were successfully selected through the lottery.
Share Allocation: Each of the lucky winners received exactly 10 shares of the company.
Advertisement
Competitive Nature: Since there were over 2.7 million valid applicants for only about 347 thousand slots, the vast majority of investors were left without an allocation.
This level of competition is common in the current Nepali primary market, where the number of DEMAT account holders has grown exponentially, often leading to oversubscriptions that exceed the available units by eight or nine times.
Next Steps for Successful and Unsuccessful Applicants
Now that the Sopan Pharmaceuticals IPO Allotment is finalized, investors need to know what follows. For the 347,490 successful applicants, the shares will be credited to their respective DEMAT accounts within a few working days. These shares will then be eligible for trading once the company completes its listing process on the Nepal Stock Exchange (NEPSE). Investors will be watching the opening price and future quarterly reports closely to assess the company’s performance in the healthcare industry.
For those who were not selected in the lottery, the funds that were blocked in their bank accounts under the C-ASBA system will be released. This unblocking process usually happens automatically after the allotment result is officially updated in the system. These investors can then utilize their capital for upcoming IPOs or other investment opportunities in the secondary market.
The Impact on Nepal’s Capital Market
The overwhelming success of this IPO is a positive signal for the entire financial ecosystem. It demonstrates that there is ample liquidity among retail investors and a strong appetite for new company listings. Sopan Pharmaceuticals’ entry into the stock market provides a fresh opportunity for investors to gain exposure to the medicine manufacturing business, which is a vital part of the national infrastructure.
The role of NMB Capital Limited as the issue manager ensured that the entire process from collection to allotment was handled with professional integrity. Such successful transactions build further trust among the public, encouraging more people to move their savings into formal investment channels.
Conclusion: A Landmark Moment for Sopan Pharmaceuticals
The completion of the Sopan Pharmaceuticals IPO Allotment marks the beginning of a new chapter for the company as a public entity. While the lottery system left many without shares, the high participation rate is a testament to the company’s reputation and the perceived value of the pharmaceutical industry. As the 347,490 new shareholders join the company, the focus now shifts toward the listing and the future growth of Sopan Pharmaceuticals on the trading floor. Investors are advised to keep their DEMAT records updated and continue monitoring the market for similar high-potential offerings in the future.
For More: Sopan Pharmaceuticals IPO Allotment
